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KEY MESSAGE
Arousal, lubrication, orgasm, sexual satisfaction and self-rated sexual attractiveness are compromised in women 
with polycystic ovary syndrome (PCOS). Yet, a satisfying sex life is as important as it is for women without 
PCOS. As PCOS is a common disorder with a potentially large psychosocial effect, these topics should be part 
of the clinical assessment.
ABSTRACT
We present the first systematic review and meta-analysis of sexual function in women with polycystic ovary syndrome 
(PCOS) compared with women without PCOS. Data on this topic are limited and often contradicting. Sexual function 
is influenced by endocrine, mental and social factors, which are often compromised in women with PCOS. The main 
outcome measures were validated sexual function questionnaires and visual analogue scales (VAS). We identified and 
assessed 1925 original articles; 18 articles were included. Significant small effect sizes were found on sexual function 
subscales (total score: P = 0.006; arousal: P = 0.019; lubrication: P = 0.023; satisfaction: P = 0.015; orgasm: 
P = 0.028), indicating impaired sexual function in women with PCOS. Large effect sizes for the effect of body hair 
on sex were shown on VAS (P = 0.006); social effect of appearance (P = 0.007); sexual attractiveness (P < 0.001). 
Satisfaction with sex life was impaired (P < 0.001), but sexual satisfaction was rated equally important in women 
with PCOS and controls. We conclude that a satisfying sex life is important for women with PCOS; however, sexual 
function and feelings of sexual attractiveness are impaired. The findings imply that sexual function, sexual satisfaction 
and psychosocial functioning need to be part of every clinical assessment of women with PCOS.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with 
an estimated prevalence of 10–15% 
worldwide (Azziz et al., 2016). The main 
characteristics are oligomenorrhoea 
or amenorrhoea, hyperandrogenism 
(biochemical or clinical) and polycystic 
ovarian morphology. A diagnosis of PCOS 
is made when at least two characteristics 
are present (Rotterdam, 2004). It is 
a distressing disorder associated with 
obesity, insulin resistance, dyslipidaemia 
and metabolic syndrome (Rotterdam, 
2004; Fauser et al., 2012). Women with 
PCOS are at risk of depression, anxiety 
and low self-esteem, and report a lower 
quality of life (Elsenbruch et al., 2003; 
Hahn et al., 2005; Elsenbruch et al.,  
2006; Himelein and Thatcher, 2006; 
De Niet et al., 2010; Mansson et al., 2011; 
Fauser et al., 2012; Veltman-Verhulst 
et al., 2012) than healthy women.
Treatment of PCOS is complex and 
varies according to symptoms and 
whether the woman has a desire to 
have children. In women who want to 
conceive, the first-line treatment is 
lifestyle modification, e.g. losing weight, 
exercise, healthy diet, followed by 
ovulation induction. Lifestyle changes 
contribute to optimizing success rates in 
establishing a pregnancy and reducing 
complication rates by normalizing weight 
and consequently insulin resistance 
(Imani et al., 2000; Imani et al., 2002; 
Mulders et al., 2003; Panidis et al., 
2013). In women who do not want to 
become pregnant, treatment usually 
consists of oral contraceptive pill (OCP) 
usage and lifestyle changes if indicated 
(Fauser et al., 2012). Both interventions 
aim at improving endocrine features by 
normalizing weight and subsequently 
insulin resistance and androgen 
metabolism. Oral contraceptive pills 
increase sex hormone binding globulin 
(SHBG) levels and hence reduce free 
androgen levels. As androgens play 
an important role in female sexual 
function, increased as well as reduced 
levels might affect sexual function 
(Bancroft, 2002; Davis et al., 2004; 
2005; Graham et al., 2007; Caruso et 
al., 2009; Basson et al., 2010). In both 
sexes, androgens mediate sexual function 
through cognitive processes such as 
sexual fantasies (Bancroft, 2003). Hence, 
elevated androgen levels might affect 
sexual function indirectly (Bancroft, 
2002; Basson et al., 2010), as found 
with hormonal contraception treatment 
(Zimmerman et al., 2014).
Research into PCOS has focused mainly 
on improving treatment options and 
pregnancy outcome (Thessaloniki, 2008); 
however, research on the psychosocial 
aspects of PCOS or sexual function has 
only recently emerged. Data on sexual 
function in women with PCOS are 
limited and often contradicting.
Sexual function is a complex 
biopsychosocial phenomenon, as is 
PCOS. In women with PCOS, sexual 
function can be influenced by many 
factors. It is known that sexual function 
can be impaired by androgen levels 
(Bancroft, 2002; Davis et al., 2004; 
Davis et al., 2005; Graham et al., 2007; 
Caruso et al., 2009; Basson et al., 2010), 
obesity (Shah, 2009; Kolotkin et al., 
2012), metabolic syndrome (Borges et 
al., 2009; Miner et al., 2012), subfertility 
(Wischmann, 2010; Ferraresi et al., 
2013a; Wischmann, 2013; Piva et al., 
2014), mental health (Kalmbach et al., 
2012; Kalmbach et al., 2014; Kalmbach 
et al., 2015; Waldinger, 2015), body 
image (Woertman and van den Brink, 
2012; van den Brink et al., 2013) and self-
esteem (Dove and Wiederman, 2000; 
Hartmann et al., 2002; Middleton et 
al., 2008). These factors are commonly 
present in women with PCOS and 
could be contributing to their sexual 
dysfunction.
The aim of this systematic review 
and meta-analysis is to present a 
comprehensive overview of research on 
sexual function in women suffering from 
PCOS.
MATERIALS AND METHODS
Search strategy
The following electronic databases 
were searched from inception until 
30 June 2017: Embase, Medline (via 
Ovid), Web-of-Science Core Collection, 
Scopus, PsycINFO (via Ovid), Cinahl (via 
EBSCOhost), Cochrane CENTRAL (via 
Wiley) and Google Scholar. Different 
relevant search terms (thesaurus terms 
and terms in title, abstract, or both) 
concerning PCOS and sexual function 
were used. To optimize the search, no 
restrictions on date, type of publication 
or language were applied. We present 
the used search strings in Supplementary 
TABLE 1. In addition to the electronic 
search, all reference lists of relevant 
reviews and included articles were 
reviewed to identify additional relevant 
articles.
Inclusion and exclusion criteria
After the electronic search, two authors 
independently selected the studies and 
considered all those addressing PCOS 
and sexual function for inclusion. To 
be selected for inclusion, the following 
criteria were used: diagnosis of PCOS 
by Rotterdam criteria, the former and 
current National Institutes of Health 
definition or the Androgen Excess and 
PCOS Society definition (Zawadzki, 
1990; Rotterdam, 2004; Azziz et al., 
2009); adequate definition of sexual 
function (operationalized as desire, 
arousal, lubrication, orgasm, frequency 
of intercourse, masturbation frequency, 
sexual dysfunction, sexual satisfaction, 
sexual self-image, sexual debut and sexual 
distress); the use of validated sexuality 
questionnaires or visual analogue scales 
(VAS); inclusion of a control group 
without PCOS; age 14 years and older. 
For inclusion, studies had to be original, 
available as full-text and written in English.
Studies unrelated to PCOS, PCOS 
induced by valproate use, or PCOS 
in combination with other illness or 
disease, were excluded. Moreover, 
studies solely concerning health-related 
quality of life, quality of life or mental 
health, and studies concerning idiopathic 
hyperandrogenism or hyperandrogenism 
caused by other diseases than PCOS, 
were also excluded. Review articles, 
PhD theses, abstracts and posters were 
also excluded. Initially, a selection was 
made based on title and abstract. Then, 
inclusion and exclusion criteria that were 
determined in advance were applied. 
Finally, all discrepancies in choices were 
discussed.
Data extraction
The following data were extracted 
from identified studies: study design, 
publication date, study period, country, 
sample size, diagnostic criteria for PCOS, 
patient and control selection procedures, 
response or participation rate, inclusion 
and exclusion criteria for cases and 
controls, age of population, outcome 
measures and intervention.
Quality assessment
We used the Newcastle–Ottawa Quality 
Assessment Scale (NOS), designed to 
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assess study quality of non-randomized 
studies, including case-control and 
cohort studies. The selection of study 
groups, comparability of groups and 
ascertainment of either exposure or 
outcome of interest for case-control or 
cohort studies were assessed in each 
study (Wells, 2010). A maximum of 10 
stars can be awarded using the NOS. 
As the NOS does not measure quality 
of outcome measures and of statistical 
analysis and reporting, two scales taken 
from the Quality in Prognostic Studies 
(QUIPS) tool were included in our quality 
assessment (Hayden et al., 2013). The 
QUIPS awards bias ratings (low, medium, 
high) using several prompting items for 
each domain. Two authors independently 
assessed the quality of the included 
studies.
Outcome measures
Sexual function was measured using 
validated questionnaires. Here, we 
present the questionnaires and, in square 
parenthesis, names of (sub)scales that 
were used in the statistical analysis. 
The Female Sexual Function Index 
(FSFI) consists of 19 items measuring 
six domains [total score, desire, arousal, 
lubrication, orgasm, satisfaction, pain] 
(Rosen et al., 2000; Wiegel et al., 2005). 
The Changes in Sexual Functioning 
Questionnaire (CSFQ) measures changes 
in sexual functioning related to illness 
and medication, with five domains [total 
score, desire/interest, desire/frequency, 
arousal/excitement, orgasm/completion, 
pleasure/satisfaction] (Clayton et al., 
1997a; 1997b). The Sexual Quotient-
Female (SQ-F) evaluates female sexual 
function with 10 questions in six domains 
[total score] (Abdo, 2006). The McCoy 
nine-item Female Sexuality Questionnaire 
(MFSQ) measures several sexual function 
indices [enjoyment, satisfaction, sexual 
thoughts, arousal, orgasm, lubrication, 
pain] (McCoy, 2000). The Female Sexual 
Desire Questionnaire (FSDQ) has 50 
items divided over six domains [dyadic 
desire] (Goldhammer and McCabe, 
2011). The Multidimensional Sexuality 
Questionnaire has 12 subscales [sexual 
satisfaction] (Snell, 1993). For all scales, 
higher scores are indicative of better 
sexual function. Finally, the Index of 
Sexual Satisfaction (ISS) measures sexual 
satisfaction [total score], with a lower 
total score indicating more satisfaction 
(Hudson et al., 1981).
Seven questions scored with VAS 
were available for our analysis: (1) how 
important is a satisfying sex life for 
you? (2) How many sexual thoughts 
and fantasies did you have in the past 
4 weeks? (3) Do you find yourself sexually 
attractive? (4) How much does excessive 
body hair impact your sexuality? (5) 
Does your appearance make it difficult 
to engage in social contact? (6) How 
often did you experience pain during 
intercourse in the past 4 weeks? (7) How 
satisfied were you with your sex life in the 
past 4 weeks? (Elsenbruch et al., 2003; 
Hahn et al., 2005; Tan et al., 2008; 
Caruso et al., 2009).
Statistical methods and meta-analysis
Meta (Schwarzer, 2015) in R (version 
3.4.0 (2017-04-21) was used for meta-
analyses. Differences between PCOS 
and control women are expressed 
in standardized mean differences 
(SMD) and presented in forest plots 
(Supplementary FIGURE 1A; Supplementary 
FIGURE 1B; Supplementary FIGURE 2; and 
Supplementary FIGURE 3). For studies 
reporting medians and quartiles, the 
median was applied as a best estimate of 
the mean, and the SD was estimated as 
34/50 of the interquartile range (34/60 
for a study reporting an interquintile 
range). Reported standard errors were 
multiplied by √n to obtain the standard 
deviation. For studies that used the 
same control group, the number of 
participants in the control group was 
adjusted to prevent an unduly heavy 
weight of this one control group. For 
sensitivity analysis, studies were excluded 
one-by-one (Sutton AJ, 2000), and 
outliers were defined when changes in 
the direction or the significance of the 
effect were detected.
In line with Cohen’s evaluation of effect 
sizes, a SMD of 0.20 is considered 
a small effect, 0.50 a medium effect 
and 0.80 a large effect (Cohen, 1992). 
Heterogeneity is reported with the I² 
statistic. The significance of heterogeneity 
was determined with Cochran’s Q 
statistic. In case of heterogeneity, Baujat 
plots were evaluated to determine which 
studies caused the heterogeneity (Baujat 
et al., 2002). Conclusions were based 
on random effect procedures to correct 
for unexplained heterogeneity of the 
studies. The random effects model uses 
a weighted average resulting in assigning 
more equal weights to all studies.
In the included case intervention studies, 
only baseline scores were used in the 
statistical analysis.
RESULTS
Search results
The result of the systematic literature 
search is presented in FIGURE 1. Eighteen 
studies were eligible, representing a 
total number of 3903 participants. 
Eight studies used the FSFI (Gateva 
and Kamenov, 2012; Ercan et al., 2013; 
Ferraresi et al., 2013b; Benetti-Pinto et 
al., 2015; Lara et al., 2015; Noroozzadeh 
et al., 2016; Shafti and Shahbazi, 2016; 
Diamond et al., 2017). Other studies 
used different scales: the CSFQ (Stovall 
et al., 2012), the SQ-F (Zueff et al., 
2015), the MFSQ (Mansson et al., 2011), 
the FSDQ (Elkhiat et al., 2015), the ISS 
(Drosdzol et al., 2007) and the MSQ 
(Kowalczyk et al., 2015). Four studies 
used VAS to assess sexual function and 
effect of clinical characteristics on sexual 
function (Elsenbruch et al., 2003; Hahn 
et al., 2005; Tan et al., 2008; Caruso 
et al., 2009). Study characteristics are 
presented in TABLE 1 and Supplementary 
TABLE 2. Reasons for exclusion are 
presented in Supplementary TABLE 3 and 
Supplementary TABLE 4.
Quality assessment
The quality assessment of the included 
studies using NOS and QUIPS is presented 
in TABLE 2. The included studies are of 
medium to low quality. The main problems 
are as follows: comparability of cases and 
controls, ascertainment of the PCOS 
exposure, reporting of response rate and 
the quality of the statistical analyses.
META-ANALYSIS
Sexual function
The sexual function scales showed small 
but significant differences between 
women with PCOS and controls 
(TABLE 3). The complete analysis showed 
no significant differences on the total 
scale score and on most subscales, 
except satisfaction, in women with 
PCOS compared with control women. 
Baujat plots (not presented) indicated 
that the study by Mansson et al. (2011) 
was an outlier for orgasm. Also, the 
study by Diamond et al. (2017) was an 
outlier for the total score as well as for 
the subscales arousal and lubrication. 
Therefore, we also conducted a sensitivity 
analysis without these studies (TABLE 3). 
The results on the four scales changed. 
Women with PCOS scored significantly 
lower on total score (SMD = –0.21; 
P = 0.006), arousal (SMD = –0.16; 
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P = 0.019), lubrication (SMD = –0.15; 
P = 0.023) and orgasm (SMD = –0.17; 
P = 0.028).
Using VAS scores, women with PCOS 
reported significantly fewer sexual thoughts 
(SMD = –0.29; P = 0.004) than controls. 
No differences in the experience of pain 
during intercourse were found (TABLE 3).
Sexual satisfaction
The subscale satisfaction showed 
a significant small sized difference 
between PCOS and control women 
(SMD = –0.26; P = 0.015); women with 
PCOS were less satisfied with their sex 
life than control women (Table 3). This 
result did not change in the sensitivity 
analysis. The studies that caused 
heterogeneity were Mansson et al. (2011) 
and Benetti Pinto et al. (2015), which 
showed larger differences.
Using VAS scores, no differences in the 
importance of a satisfying sex life were 
found between women with PCOS 
and control women (SMD = 0.03; 
P = 0.544). Satisfaction with sex life, 
however, showed a significant large sized 
difference (SMD = –0.96; P < 0.001), 
with women with PCOS scoring lower 
than controls (TABLE 3).
Effect of clinical characteristics
On all three VAS scales, significant 
differences were found, showing 
disadvantages for women with PCOS: 
Do you find yourself sexually attractive? 
(SMD = –0.80; P < 0.001); how much 
does excessive body hair impact your 
sexuality? (SMD = 1.01; P < 0.006); does 
your appearance make it difficult to 
engage in social contact? (SMD = 0.65; 
P < 0.007) (Table 3). Baujat plots indicated 
that the study that caused heterogeneity 
for body hair and attractiveness was 
Caruso et al. (2009), with women with 
PCOS scoring exceptionally worse.
Effect of treatment interventions
Three included studies were intervention 
studies. It was not possible to assess the 
effect of interventions on sexual function 
in women with PCOS because all studies 
used different treatments: chlormadinone 
acetate (Caruso et al., 2009), metformin 
(Gateva and Kamenov, 2012) and 
resistance training (Lara et al., 2015).
DISCUSSION
This meta-analysis shows impaired sexual 
function in women with PCOS compared 
with control women; effect sizes were 
small to large. Sexuality questionnaires 
show small impairments, particularly 
arousal, lubrication, orgasm and sexual 
satisfaction.
In addition, based on VAS scores, 
women with PCOS reported fewer sexual 
thoughts and fantasies and less chance 
of establishing relationships compared 
with control women. Large impairments 
were reported on sexual attractiveness, 
satisfaction with their sex life and the 
effect of their physical appearance and 
body hair on sexuality. The effect sizes 
FIGURE 1 Literature search.
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TABLE 1 STUDY CHARACTERISTICS OF THE INCLUDED STUDIES.
Study Design PCOS 
 definition
Outcome 
measure
Interven-
tion
Year Country Age / 
range
n Selection population; 
response rate
Elsenbruch 
et al., 
2003
Cross- 
sectional
NICHD VAS NA – Germany 20–40 PCOS 
50
Outpatient endocrine clinic; 
website clinic
Controls 
50
Health screening programme; 
university
Hahn et al., 
2005
Cross- 
sectional
NICHD VAS NA – Germany PCOS PCOS 
120
Outpatient endocrine clinic;
Rotterdam criteria M = 29 website clinic
Controls 
M = 30
Controls 
50
Health screening programme; 
university
Drosdzol 
et al., 2007
Cross- 
sectional
ESHRE, 
 Rotterdam criteria
ISS NA – Poland 19–40 PCOS 
50
University Hospital: Obstetrics 
and Gynaecology and Gynae-
cological Endocrinology
Controls 
40
Outpatient Gynaecological 
Clinics
Tan et al., 
2008
Cross- 
sectional
NICHD 
 Rotterdam criteria
VAS NA – Germany PCOS 
M = 28
PCOS 
115
Outpatient endocrine clinic; 
response rate near 100%
Controls 
M = 30
Controls 
50
Health screening programme; 
university
Caruso 
et al., 
2009
Prospective 
intervention
Rotterdam criteria VAS Oral 
 contraceptive
– Italy 18–32 PCOS 94 Family planning centre; 
 response rate 79%
Controls 
50
Health screening programme; 
university
Mansson 
et al., 2011
Case 
control
Rotterdam criteria McCoy- 
FSQ
NA 2002-
2005
Sweden – PCOS 49 Linné Infertility Clinic, 
 Department of Obstetrics and 
Gynaecology and Medicine 
University Hospital, support 
community homepage
Controls 
49
Population registry
 Gateva 
and 
Kamenov, 
2012
Cross- 
 sectional
ESHRE FSFI Metformin – Bulgaria 18–45 PCOS 57 Hospitalized patient endocrine 
clinic
ASRM Controls 
22
Other hospital population
Stovall 
et al., 2012
Cross- 
 sectional
NICHD CSFQ NA 2006–
2009
USA 18–43 PCOS 92 Convenient; hospital
Controls 
82
Waiting room university 
 gynaecological department
Ercan 
et al., 2013
Cross- 
sectional
Rotterdam criteria FSFI NA – Turkey 20–40 PCOS 32 Not specified; hospital; 
 response rate 93%
Controls 
32
University hospital; routine 
check up
Ferraresi 
et al., 2013
Cross- 
sectional
Rotterdam criteria FSFI NA 2008–
2010
Brazil 18–38 PCOS 48 Consecutive sample; tertiary; 
hospital; response rate 83/87 
total population
Controls 
35
Primary care same hospital; 
regular menses
Zueff 2 
et al., 2014
Case 
control
Rotterdam criteria SQ-F NA 2009–
2010
Brazil 18–40 PCOS 43 Outpatient gynaecology; 
 contraception programme
Controls 
44
Outpatient gynaecology; 
 contraception programme
Benetti- 
Pinto et al., 
2015
Cross- 
sectional
Rotterdam criteria FSFI NA – Brazil 18–40 PCOS 56 Gynaecology department 
university hospital; response 
rate 100%
Controls 
102
Gynaecology department 
university hospital; response 
rate 100%
Elkhiat 
et al., 2015
Cross- 
sectional
Medical screening 
according to Rot-
terdam criteria
FSDQ NA – Egypt 21–45 PCOS 85 Gynecology and Obstetrics 
Clinic
Controls 
63
Gynecology and Obstetrics 
Clinic
(Continued)
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suggest that these concerns are clinically 
relevant.
Anxiety, depression (Kalmbach et al., 
2012; Kalmbach et al., 2014) and poor 
body image (Woertman and van den 
Brink, 2012) are recognized psychosocial 
risk factors for sexual dysfunction and 
impaired sexual satisfaction. The VAS 
scores in our analysis also suggests that a 
poor body image in women with PCOS 
may make them more prone to sexual 
dysfunction compared with women 
without PCOS.
The finding that arousal, lubrication, 
orgasm and sexual satisfaction were 
impaired in women with PCOS but that 
dyspareunia (pain during intercourse) 
was not more common than in controls 
is intriguing. An explanation for this 
discrepancy may be that dyspareunia is 
also highly prevalent in women without 
a medical condition (Mitchell et al., 
2017). Dyspareunia is not associated 
with one’s capacity to become genitally 
and subjectively aroused (Brauer et al., 
2006) but seems related to the habit of 
prioritizing a partner’s pleasure over one’s 
own (Elmerstig et al., 2013; Kontula and 
Miettinen, 2016), resulting in engaging 
in intercourse before being fully sexually 
aroused (Brauer et al., 2014). The net 
result of such behaviour dominates 
a possible worse dyspareunia rate in 
women without PCOS.
The study by Diamond et al. (2017), 
with a proportionately high number 
of participants relative to the other 
studies, significantly dominated the 
overall pattern of results. The analyses, 
including the latter study (Diamond 
et al., 2017), found fewer differences in 
sexual function and sexual satisfaction 
between women with PCOS and controls 
than the analyses excluding this study. 
The women with PCOS in this study 
(Diamond et al., 2017) represented a 
selected group of infertile individuals 
who were highly motivated to conceive, 
and who participated in a clinical trial 
to evaluate fertility treatment outcome. 
Study design characteristics may have 
artificially increased sexuality indices in 
women with PCOS. Participants were 
instructed to have intercourse at least 
two to three times a week (Legro et al., 
2012; Legro et al., 2014). Combined with 
being highly motivated to conceive, this 
might have directly enhanced intercourse 
frequency. Additionally, the main 
outcome measure, the FSFI, is designed 
such that women who do not engage 
in intercourse in the 4 weeks before 
assessment, even if this is unrelated to 
Study Design PCOS 
 definition
Outcome 
measure
Interven-
tion
Year Country Age / 
range
n Selection population; 
response rate
Kowalczyk 
et al., 2015
Cross- 
sectional
Rotterdam criteria MSQ NA 2009 Poland 23–42 PCOS 73 University hospital: department 
of Gynaecologic Endocrinology
Response rate 117/128
Controls 
45
Outpatient clinic of Women’s 
Health Diagnostic Centre; 
response rate 45/50
Lara et al., 
2015
Case 
control
Rotterdam FSFI Physical resist-
ance training
2010–
2013
Brazil 18–37 PCOS 
43
Endocrine gynaecology 
 outpatient clinic, academic 
medical centre
Controls 
51
Endocrine gynaecology 
 outpatient clinic; academic 
medical centre
Noroozza-
deh et al., 
2016
Cross-sec-
tional 
population 
based
Rotterdam criteria FSFI NA – Iran 18–45 PCOS 63 Stratified-cluster sampling 
method in four provinces of 
various geographic regions 
of Iran, no response rate, 
flowchart with number of 
participants
Controls 
216
Stratified-cluster sampling 
method in four provinces of 
various geographic regions 
of Iran; no response rate; 
flowchart with number of 
participants
Shafti and 
Shahbazi, 
2016
Casual 
comparative 
study
Rotterdam criteria FSFI NA 2013–
2014
Iran 18–45 PCOS 
129
Hospital and women infertility 
clinics
Controls 
125
Convenient sample
Diamond 
et al., 2017
Clinical trial Rotterdam criteria FSFI Letrozole or 
clomiphene/ 
gonadotropins
– USA 18–39 PCOS 
733
PPCOS II trial; response rate 
97.7%
18–40 Controls 
865
AMIGOS trial; response rate 
96.1%
ASR, American Society of Reproduction; CSFQ, Changes in Sexual Function Questionnaire; ESHRE, European Society of Human Reproduction and Embryology; FSFI, 
Female Sexual Function Index; FSDQ, Female Sexual Desire Questionnaire; ISS, Index of Sexual Satisfaction; M, mean; McCoy-FSQ, McCoy Female Sexuality Question-
naire; NA, not applicable; NICHD, National Institute of Child Health and Human Development; MSQ, Multidimensional Sexuality Questionnaire; PCOS, polycystic ovary 
syndrome; SQ-F, Sexual Quotient- Female; VAS, visual analogue scale.
TABLE 1 (CONTINUED)
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TABLE 2 QUALITY ASSESSMENT OF SELECTED PUBLICATIONS APPLYING THE NEWCASTLE–OTTAWA QUALITY 
 ASSESSMENT SCALE AND THE QUALITY IN PROGNOSTIC STUDIES.a,b
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Elsenbruch 
et al., 2003
* * - * * - * - MB MB
Hahn et al., 
2005
* * - * - - * - HB MB
Drosdzol et 
al., 2007
* * - - * - - - LB MB
Tan et al., 
2008
* * - * - - * - HB MB
Caruso et 
al., 2009
* * - * - - * - HB MB
Mansson et 
al., 2011
* * * * * - - - LB HB
Gateva et 
al., 2012
* - * - ** - * - LB MB
Stovall et al., 
2012
* * - - ** - * - LB MB
Ercan et al., 
2013
* * * * * - * - LB MB
Ferraresi et 
al., 2013
* * - - * - * - LB MB
Zueff et al., 
2014
* - * - ** - * - LB MB
Benetti Pinto 
et al., 2015
* * * - * - * - LB LB
Elkhiat et al., 
2015
* - - - * - * - LB MB
Kowalczyk 
et al., 2015
* * - * ** - - * LB MB
Lara et al., 
2015
- * - * * - * - LB LB
Noroozzade
h et al., 2017
* * * * * - * - LB LB
Shafti and 
Shahbazi, 
2016
* * - - * - * - LB HB
Diamond et 
al., 2017
* - - * ** - * * LB LB
/ 
a
Outcome category: High bias: The measurement of the outcome is likely to be different related to the baseline level 
of the prognostic factor; Moderate bias: the measurement of the outcome may be different related to the baseline 
level of the prognostic factors; low bias: the measurement of the outcome is unlikely to be different related to the 
baseline level of the prognostic factor
b
Statistical analysis and reporting: High bias: the reported results are likely to be spurious or biased related to 
analysis or reporting; Moderate bias: the reported results may be spurious or biased related to analysis or reporting; 
Low bias: the reported results are unlikely to be spurious or biased related to analysis or reporting.
c
NOS: a study can be awarded a maximum of one star for each item, except for the Comparability category and
Exposure ascertainment (a maximum of two stars). 
*, adequate; -, not adequate; green, no risk or low risk of bias; orange, medium risk of bias; red, high risk of bias; HB, 
high risk of bias LB, low risk of bias; MB, medium risk of bias; NOS, Newcastle–Ottawa Quality Assessment Scale 
QUIPS, Quality in Prognostic Studies;  
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sexual dysfunction, have significantly 
lower FSFI total scores than women who 
do engage in intercourse within this time 
frame. The study’s instructions to have 
sexual intercourse, together with the 
high proportion of FSFI items that refer 
to sexual intercourse,inflate FSFI total 
scores. For these reasons, we conclude 
that the analysis excluding Diamond et al. 
(2017) may provide a better estimation 
of the sexual function status of women 
with PCOS than the analysis including 
this study.
To date, it is unclear if, and to what 
extent, androgen levels of women with 
and without PCOS are related to sexual 
function. In several studies, normalizing 
androgen levels in women with PCOS 
was found to be unrelated to changes 
in levels of sexual desire (Conaglen and 
Conaglen, 2003; Caruso et al., 2009). 
This may suggest that androgen levels 
are irrelevant for the sexual function 
of women with PCOS. Alternatively, 
perhaps an optimal balance of hormonal 
milieu is required for sex-hormones to 
influence sexual function or, perhaps, 
critical levels of other hormones such 
as oestradiol and progesterone are also 
required for normal sexual functioning 
(Wierman et al., 2010). Finally, there 
may be a normal hormonal range 
between which women show normal 
sexual function (Wierman et al., 2010). 
Women with PCOS might well exceed 
this range.
Although the influence of endocrine 
factors in women with PCOS is far 
from elucidated, treatment with OCP 
is regarded standard clinical care, even 
though OCP may not decrease androgen 
levels to the normal hormonal range. 
In women with PCOS, progesterone 
feedback and progesterone serum levels 
are also compromised (Burt Solorzano et 
al., 2012), potentially adding to the effect 
that different sex steroids may have on 
sexual function.
Several studies have shown that use of 
OCP is related to a decrease in androgen 
levels in healthy women, potentially 
impairing sexual function (Burrows et 
al., 2012; Davis et al., 2013; Zimmerman 
et al., 2014; Higgins and Smith, 2016), 
whereas others did not (Graham et al., 
1995; Sanders et al., 2001; Graham et 
al., 2007). Perhaps no single androgen 
level is predictive of low female sexual 
function (Davis et al., 2005). The scope 
of this study was not on the effect 
TABLE 3 AGGREGATED POLYCYSTIC OVARY SYNDROME AND CONTROL GROUP ESTIMATES BASED ON FSFI, ISS, 
MCCOY–FSQ, CSQF, SQ–F, FSDQ & MSQ SCALES AND VAS SCALES.
K N Random effects Heterogeneity
Questionnaires  
scales 
PCOS Controls SMD 95% CI P-value Q(df) P-value
Total 10 1097 1444 –0.12 [–0.24 to 0.00] NS 10.9(9) NS
Desire 10 1263 1596 –0.02 [–0.52 to 0.47] NS 90.4(9) <0.001
Arousal 9 1177 1535 –0.07 [–0.17 to 0.03] NS 8.4(8) NS
Lubrication 8 1081 1449 –0.05 [–0.14 to –0.04] NS 5.6(7) NS
Orgasm 9 1177 1532 –0.11 [–0.36 to 0.13] NS 23.9(8) 0.002
Satisfaction 11 1305 1622 –0.26 [–0.46 to –0.06] 0.015 32.3(10) <0.001
Pain intercourse 8 1085 1450 –0.06 [–0.21 to 0.09] NS 9.9(7) NS
Outliers excluded
Totala 9 363 584 –0.21 [–0.34 to –0.08] 0.006 5.1(8) NS
Arousala 8 446 675 –0.16 [–0.28 to 0.04] 0.019 4.6(7) NS
Lubricationa 7 350 589 –0.15 [–0.26 to –0.03] 0.023 2.8(6) NS
Orgasmb 8 1135 1490 –0.17 [–0.23 to –0.03] 0.028 12.4(7) NS
VAS scalesc
Importance of  
satisfactory sex life
4 282 50 0.03 [–0.10 to 0.16] NS 0.21(3) NS
Thoughts 4 282 50 –0.29 [–0.40 to –0.17] 0.004 0.16(3) NS
Attractive 5 354 50 –0.80 [–0.92 to –0.68] <0.001 0.31(4) NS
Body hair 5 354 50 1.01 [0.49 to 1.52] 0.006 5.49(4) NS
Social impact 5 354 50 0.65 [0.30 to 1.01] 0.007 2.71(4) NS
Pain intercourse 3 162 50 0.23 [–0.23 to 0.70] NS 0.89(2) NS
Satisfaction with sex life 4 282 50 –0.96 [–1.06 to –0.85] <0.001 0.13(3) NS
CSFQ, Changes in Sexual Function Questionnaire; FSDQ, Female Sexual Desire Questionnaire; FSFI, Female Sexual Function Index; ISS, Index of Sexual Satisfaction; 
K, number of entries; McCoy–FSQ, McCoy Female Sexuality Questionnaire; MSQ, Multidimensional Sexuality Questionnaire; N, number of participants; PCOS, polycystic 
ovary syndrome; Q(df), Cochran's Q; SMD, standardized mean difference; SQ–F, Sexual Quotient–Female; VAS, visual analogue scale.
a Diamond et al., (2017) excluded.
b Manson et al. (2011) excluded.
c Numbers of control groups adjusted to avoid an unduly heavy weight of the one control group.
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of endocrine factors. Also, it was not 
possible to stratify for OCP use or 
endocrine factors potentially obscuring 
the results.
Sexual function studies in women 
with other hyperandrogenic disorders 
are relatively scarce. Several studies 
in women with congenital adrenal 
hyperplasia (CAH) have been published 
over the past 2 decades, with many of 
them focusing on gender identity, gender 
role behaviour, sexual orientation and age 
of sexual debut (Dittmann et al., 1992; 
Zucker et al., 1996; Jaaskelainen et al., 
2001; Hines et al., 2004; Wisniewski et 
al., 2004; Zucker et al., 2004; Meyer-
Bahlburg et al., 2008; Frisen et al., 
2009). Studies in women with CAH 
focus on sexual function reported 
impaired sexual function as assessed 
with the FSFI (Gastaud et al., 2007; van 
der Zwan et al., 2013; Krysiak et al., 
2016). These women were found to have 
significantly lower FSFI total and subscale 
scores compared with healthy controls. 
Although some discrepant findings 
were observed between studies, overall, 
women with CAH did report impaired 
sexual function.
An important strength of the present 
study is that it represents the first 
systematic quantitative analysis of the 
relationship between PCOS and sexual 
function. The studies included in this 
meta-analysis were carefully assessed 
for quality using well-known Cochrane 
tools (Wells, 2010; Hayden et al., 
2013).
The main limitation of this study is the 
relatively low number of publications 
that could be used for the meta-analysis. 
Also, study quality is limited, which 
may negatively affect the reliability of 
the findings. This limitation may be 
particularly relevant for the studies that 
used VAS scores (Elsenbruch et al., 
2003; Hahn et al., 2005; Tan et al., 
2008; Caruso et al., 2009). These four 
studies used the same control group of 
50 women that participated in the study 
by Elsenbruch et al. (2003) (TABLE 1 and 
Supplementary TABLE 2). In this control 
group, PCOS was explicitly excluded, but 
the control group may not have been 
fully matched with the PCOS group in all 
four studies. We prevented this specific 
control group having an unduly heavy 
weight in the analysis by entering a total 
of 50 controls, but also conducted a 
sensitivity analysis in which each control 
group counted separately for each entry. 
Changes in results were negligible.
Another limitation is the diversity 
between the studies; for example four 
studies were from Islamic countries, 
including only married women (Ercan 
et al., 2013; Elkhiat et al., 2015; 
Noroozzadeh et al., 2016; Shafti and 
Shahbazi, 2016). Other studies did not 
mention relationship status or sexual 
activity of participants (Gateva and 
Kamenov, 2012; Stovall et al., 2012; Lara 
et al., 2015). This diversity might imply 
that groups are not comparable.
More studies of sexual function in women 
with PCOS are warranted. As PCOS and 
sexual function are both biopsychosocial 
phenomena, studies should also use a 
biopsychosocial design. This would mean 
assessing psychosocial aspects using 
questionnaires, evaluating endocrine 
and genetic features and measuring 
genital responses to sexual stimuli, using 
psychophysiological measurements. Also, 
ideally, partners’ sexual function and 
sexual satisfaction should be included.
In conclusion, our findings indicate that 
women with PCOS have a compromised 
sex life. Yet, a satisfying sex life is as 
important for women with PCOS as 
for women without PCOS. This implies 
that women with PCOS aspire the same 
goals of sexuality as women without 
PCOS, but that they are less able to 
reach these goals. The findings imply 
that sexual function, sexual satisfaction 
and psychosocial functioning need to be 
part of the clinical assessment of every 
woman with PCOS.
SUPPLEMENTARY MATERIALS
Supplementary material associated with 
this article can be found, in the online 
version, at doi:10.1016/j.rbmo.2018.09.010.
REFERENCES
Abdo, H.C.N. Development and validation of 
female sexual quotient - questionnaire to 
assess female sexual function. (Elaboracao 
e validacao do quociente sexual - versae 
feminina: uma escala para avaliar a funcao 
sexual da mulher). RBM Revista Brasileira de 
Medicina 2006; 63
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., 
Laven, J.S., Legro, R.S., Lizneva, D., Natterson-
Horowtiz, B., Teede, H.J., Yildiz, B.O. Polycystic 
ovary syndrome. Nat Rev Dis Primers 2016; 
2: 16057
Azziz, R., Carmina, E., Dewailly, D., Diamanti-
Kandarakis, E., Escobar-Morreale, H.F., 
Futterweit, W., Janssen, O.E., Legro, R.S., 
Norman, R.J., Taylor, A.E., Witchel, S.F. Task 
Force on the Phenotype of the Polycystic 
Ovary Syndrome of The Androgen, E. and 
Society, P.. The Androgen Excess and PCOS 
Society criteria for the polycystic ovary 
syndrome: the complete task force report. 
Fertil Steril 2009; 91: 456–488
Bancroft, J. Sexual effects of androgens in 
women: some theoretical considerations. 
Fertil Steril 2002; 77: S55–S59
Bancroft, J. Androgens and sexual function 
in men and women. Bagatell C.J.B., W. J. 
Androgens in health and disease  Humana 
Press 2003: 259–290
Basson, R., Brotto, L.A., Petkau, A.J., Labrie, 
F. Role of androgens in women’s sexual 
dysfunction. Menopause 2010; 17: 962–971
Baujat, B., Mahe, C., Pignon, J.P., Hill, C. A 
graphical method for exploring heterogeneity 
in meta-analyses: application to a meta-
analysis of 65 trials. Stat Med 2002; 21: 
2641–2652
Benetti-Pinto, C.L., Ferreira, S.R., Antunes, A.Jr., 
Yela, D.A. The influence of body weight on 
sexual function and quality of life in women 
with polycystic ovary syndrome. Arch Gynecol 
Obstet 2015; 291: 451–455
Borges, R., Temido, P., Sousa, L., Azinhais, P., 
Conceicao, P., Pereira, B., Leao, R., Retroz, E., 
Brandao, A., Cristo, L., Sobral, F. Metabolic 
syndrome and sexual (dys)function. J Sex Med 
2009; 6: 2958–2975
Brauer, M., Laan, E., ter Kuile, M.M. Sexual 
arousal in women with superficial 
dyspareunia. Arch Sex Behav 2006; 35: 
191–200
Brauer, M., Lakeman, M., van Lunsen, R., Laan, 
E. Predictors of task-persistent and fear-
avoiding behaviors in women with sexual pain 
disorders. J Sex Med 2014; 11: 3051–3063
Burrows, L.J., Basha, M., Goldstein, A.T. The 
effects of hormonal contraceptives on 
female sexuality: a review. J Sex Med 2012; 9: 
2213–2223
Burt Solorzano, C.M., Beller, J.P., Abshire, M.Y., 
Collins, J.S., McCartney, C.R., Marshall, J.C. 
Neuroendocrine dysfunction in polycystic 
ovary syndrome. Steroids 2012; 77: 332–337
Caruso, S., Rugolo, S., Agnello, C., Romano, 
M., Cianci, A. Quality of sexual life in 
hyperandrogenic women treated with an 
oral contraceptive containing chlormadinone 
acetate. J Sex Med 2009; 6: 3376–3384
Clayton, A.H., McGarvey, E.L., Clavet, G.J. The 
Changes in Sexual Functioning Questionnaire 
(CSFQ): development, reliability, and validity. 
Psychopharmacol Bull 1997; 33: 731–745
10 RBMO  VOLUME 00  ISSUE 0  2018
Clayton, A.H., McGarvey, E.L., Clavet, G.J., 
Piazza, L. Comparison of sexual functioning in 
clinical and nonclinical populations using the 
Changes in Sexual Functioning Questionnaire 
(CSFQ). Psychopharmacol Bull 1997; 33: 
747–753
Cohen, J. A power primer. Psychol Bull 1992; 112: 
155–159
Conaglen, H.M., Conaglen, J.V. Sexual desire in 
women presenting for antiandrogen therapy. J 
Sex Marital Ther 2003; 29: 255–267
Davis, S.R., Bitzer, J., Giraldi, A., Palacios, S., 
Parke, S., Serrani, M., Mellinger, U., Nappi, 
R.E. Change to either a nonandrogenic 
or androgenic progestin-containing oral 
contraceptive preparation is associated with 
improved sexual function in women with oral 
contraceptive-associated sexual dysfunction. J 
Sex Med 2013; 10: 3069–3079
Davis, S.R., Davison, S.L., Donath, S., Bell, R.J. 
Circulating androgen levels and self-reported 
sexual function in women. JAMA 2005; 294: 
91–96
Davis, S.R., Guay, A.T., Shifren, J.L., Mazer, 
N.A. Endocrine aspects of female sexual 
dysfunction. J Sex Med 2004; 1: 82–86
De Niet, J.E., De Koning, C.M., Pastoor, H., 
Duivenvoorden, H.J., Valkenburg, O., Ramakers, 
M.J., Passchier, J., De Klerk, C., Laven, J.S.E. 
Psychological well-being and sexarche in 
women with polycystic ovary syndrome. Hum 
Reprod 2010; 25: 1497–1503
Diamond, M.P., Legro, R.S., Coutifaris, C., Alvero, 
R., Robinson, R.D., Casson, P.A., Christman, 
G.M., Huang, H., Hansen, K.R., Baker, V., Usadi, 
R., Seungdamrong, A., Bates, G.W., Rosen, 
R.M., Schlaff, W., Haisenleder, D., Krawetz, 
S.A., Barnhart, K., Trussell, J.C., Santoro, 
N., Eisenberg, E., Zhang, H. Sexual function 
in infertile women with polycystic ovary 
syndrome and unexplained infertility. Am J 
Obstet Gynecol. 2017
Dittmann, R.W., Kappes, M.E., Kappes, M.H. 
Sexual behavior in adolescent and adult 
females with congenital adrenal hyperplasia. 
Psychoneuroendocrinology 1992; 17: 153–170
Dove, N.L., Wiederman, M.W. Cognitive 
distraction and women’s sexual functioning. J 
Sex Marital Ther 2000; 26: 67–78
Drosdzol, A., Skrzypulec, V., Mazur, B., Pawlinska-
Chmara, R. Quality of life and marital sexual 
satisfaction in women with polycystic ovary 
syndrome. Folia Histochem Cytobiol 2007; 45: 
93–97
Elkhiat, Y., Zedan, A., Mostafa, M., Elhalwagi, A. 
Sexual desire in a sample of married Egyptian 
women with polycystic ovarian syndrome. 
Human 2015
Elmerstig, E., Wijma, B., Swahnberg, K. 
Prioritizing the partner’s enjoyment: a 
population-based study on young Swedish 
women with experience of pain during vaginal 
intercourse. J Psychosom Obstet Gynaecol 
2013; 34: 82–89
Elsenbruch, S., Benson, S., Hahn, S., Tan, S., 
Mann, K., Pleger, K., Kimmig, R., Janssen, O.E. 
Determinants of emotional distress in women 
with polycystic ovary syndrome. Hum Reprod 
2006; 21: 1092–1099
Elsenbruch, S., Hahn, S., Kowalsky, D., Offner, 
A.H., Schedlowski, M., Mann, K., Janssen, O.E. 
Quality of Life, Psychosocial Well-Being, and 
Sexual Satisfaction in Women with Polycystic 
Ovary Syndrome. J Clin Endocrinol Metab 
2003; 88: 5801–5807
Ercan, C.M., Coksuer, H., Aydogan, U., Alanbay, 
I., Keskin, U., Karasahin, K.E., Baser, I. Sexual 
dysfunction assessment and hormonal 
correlations in patients with polycystic ovary 
syndrome. Int J Impotence Res 2013; 25: 
127–132
Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., Legro, 
R.S., Balen, A.H., Lobo, R., Carmina, E., Chang, 
J., Yildiz, B.O., Laven, J.S., Boivin, J., Petraglia, 
F., Wijeyeratne, C.N., Norman, R.J., Dunaif, A., 
Franks, S., Wild, R.A., Dumesic, D., Barnhart, 
K. Consensus on women’s health aspects 
of polycystic ovary syndrome (PCOS): the 
Amsterdam ESHRE/ASRM-Sponsored 3rd 
PCOS Consensus Workshop Group. Fertil 
Steril 2012; 97: e25
Ferraresi, S.R., Lara, L.A., de Sa, M.F., Reis, R.M., 
Rosa e Silva, A.C. Current research on how 
infertility affects the sexuality of men and 
women. Recent Pat Endocr Metab Immune 
Drug Discov 2013; 7: 198–202
Ferraresi, S.R., Lara, L.A.S., Reis, R.M., de Sa Rosa 
e Silva, A.C.J. Changes in Sexual Function 
among Women with Polycystic Ovary 
Syndrome: A Pilot Study. J Sex Med 2013; 10: 
467–473
Frisen, L., Nordenstrom, A., Falhammar, H., 
Filipsson, H., Holmdahl, G., Janson, P.O., 
Thoren, M., Hagenfeldt, K., Moller, A., 
Nordenskjold, A. Gender role behavior, 
sexuality, and psychosocial adaptation in 
women with congenital adrenal hyperplasia 
due to CYP21A2 deficiency. J Clin Endocrinol 
Metab 2009; 94: 3432–3439
Gastaud, F., Bouvattier, C., Duranteau, L., Brauner, 
R., Thibaud, E., Kutten, F., Bougneres, P. 
Impaired sexual and reproductive outcomes 
in women with classical forms of congenital 
adrenal hyperplasia. J Clin Endocrinol Metab 
2007; 92: 1391–1396
Gateva, A., Kamenov, Z. Sexual Function in 
Patients with PCOS and/or Obesity before 
and after Metformin Treatment. Advances in 
Sexual Medicine. 2012
Goldhammer, D.L., McCabe, M.P. Development 
and psychometric properties of the Female 
Sexual Desire Questionnaire (FSDQ). J Sex 
Med 2011; 8: 2512–2521
Graham, C.A., Bancroft, J., Doll, H.A., Greco, T., 
Tanner, A. Does oral contraceptive-induced 
reduction in free testosterone adversely 
affect the sexuality or mood of women?. 
Psychoneuroendocrinology 2007; 32: 246–255
Graham, C.A., Ramos, R., Bancroft, J., Maglaya, 
C., Farley, T.M. The effects of steroidal 
contraceptives on the well-being and 
sexuality of women: a double-blind, placebo-
controlled, two-centre study of combined and 
progestogen-only methods. Contraception 
1995; 52: 363–369
Hahn, S., Janssen, O.E., Tan, S., Pleger, K., Mann, 
K., Schedlowski, M., Kimmig, R., Benson, S., 
Balamitsa, E., Elsenbruch, S. Clinical and 
psychological correlates of quality-of-life in 
polycystic ovary syndrome. Eur J Endocrinol 
2005; 153: 853–860
Hartmann, U., Heiser, K., Ruffer-Hesse, C., Kloth, 
G. Female sexual desire disorders: subtypes, 
classification, personality factors and new 
directions for treatment. World J Urol 2002; 
20: 79–88
Hayden, J.A., van der Windt, D.A., Cartwright, 
J.L., Cote, P., Bombardier, C. Assessing bias in 
studies of prognostic factors. Ann Intern Med 
2013; 158: 280–286
Higgins, J.A., Smith, N.K. The Sexual 
Acceptability of Contraception: Reviewing the 
Literature and Building a New Concept. J Sex 
Res 2016; 53: 417–456
Himelein, M.J., Thatcher, S.S. Polycystic ovary 
syndrome and mental health: A review. Obstet 
Gynecol Surv 2006; 61: 723–732
Hines, M., Brook, C., Conway, G.S. Androgen 
and psychosexual development: core gender 
identity, sexual orientation and recalled 
childhood gender role behavior in women 
and men with congenital adrenal hyperplasia 
(CAH). J Sex Res 2004; 41: 75–81
Hudson, W.W., Harrison, D.F., Crosscup, P.C. A 
Short-Form Scale to Measure Sexual Discord 
in Dyadic Relationships. Journal of Sex 
Research 1981; 17: 157–174
Imani, B., Eijkemans, M.J., de Jong, F.H., Payne, 
N.N., Bouchard, P., Giudice, L.C., Fauser, 
B.C. Free androgen index and leptin are the 
most prominent endocrine predictors of 
ovarian response during clomiphene citrate 
induction of ovulation in normogonadotropic 
oligoamenorrheic infertility. J Clin Endocrinol 
Metab 2000; 85: 676–682
Imani, B., Eijkemans, M.J., te Velde, E.R., 
Habbema, J.D., Fauser, B.C. A nomogram 
to predict the probability of live birth after 
clomiphene citrate induction of ovulation 
in normogonadotropic oligoamenorrheic 
infertility. Fertil Steril 2002; 77: 91–97
Jaaskelainen, J., Tiitinen, A., Voutilainen, R. Sexual 
function and fertility in adult females and 
males with congenital adrenal hyperplasia. 
Horm Res 2001; 56: 73–80
Kalmbach, D.A., Ciesla, J.A., Janata, J.W., 
Kingsberg, S.A. Specificity of anhedonic 
depression and anxious arousal with sexual 
problems among sexually healthy young 
adults. J Sex Med 2012; 9: 505–513
Kalmbach, D.A., Kingsberg, S.A., Ciesla, J.A. How 
changes in depression and anxiety symptoms 
correspond to variations in female sexual 
response in a nonclinical sample of young 
women: a daily diary study. J Sex Med 2014; 
11: 2915–2927
Kalmbach, D.A., Pillai, V., Kingsberg, S.A., Ciesla, 
J.A. The Transaction Between Depression and 
Anxiety Symptoms and Sexual Functioning: A 
Prospective Study of Premenopausal, Healthy 
Women. Arch Sex Behav 2015; 44: 1635–1649
Kolotkin, R.L., Zunker, C., Ostbye, T. Sexual 
functioning and obesity: a review. Obesity 
(Silver Spring) 2012; 20: 2325–2333
Kontula, O., Miettinen, A. Determinants of female 
sexual orgasms. Socioaffect Neurosci Psychol 
2016; 6: 31624
Kowalczyk, R., Skrzypulec-Plinta, V., Nowosielski, 
K., Lew-Starowicz, Z. Sexuality in women with 
polycystic ovary syndrome. Ginekol Pol 2015; 
86: 100–106
Krysiak, R., Drosdzol-Cop, A., Skrzypulec-Plinta, V., 
Okopien, B. Sexual Function and Depressive 
Symptoms in Young Women With Nonclassic 
Congenital Adrenal Hyperplasia. J Sex Med 
2016; 13: 34–39
Lara, L.A.S., Ramos, F.K.P., Kogure, G.S., Costa, 
R.S., Silva de Sá, M.F., Ferriani, R.A., dos Reis, 
R.M. Impact of Physical Resistance Training 
on the Sexual Function of Women with 
Polycystic Ovary Syndrome. J Sex Med 2015; 
12: 1584–1590
Legro, R.S., Brzyski, R.G., Diamond, M.P., Coutifaris, 
C., Schlaff, W.D., Casson, P., Christman, G.M., 
Huang, H., Yan, Q., Alvero, R., Haisenleder, D.J., 
 RBMO  VOLUME 00  ISSUE 0  2018 11
Barnhart, K.T., Bates, G.W., Usadi, R., Lucidi, S., 
Baker, V., Trussell, J.C., Krawetz, S.A., Snyder, P., 
Ohl, D., Santoro, N., Eisenberg, E., Zhang, H., 
Network, N.R.M. Letrozole versus clomiphene 
for infertility in the polycystic ovary syndrome. 
N Engl J Med 2014; 371: 119–129
Legro, R.S., Kunselman, A.R., Brzyski, R.G., 
Casson, P.R., Diamond, M.P., Schlaff, W.D., 
Christman, G.M., Coutifaris, C., Taylor, H.S., 
Eisenberg, E., Santoro, N., Zhang, H., Network, 
N.R.M. The Pregnancy in Polycystic Ovary 
Syndrome II (PPCOS II) trial: rationale and 
design of a double-blind randomized trial 
of clomiphene citrate and letrozole for 
the treatment of infertility in women with 
polycystic ovary syndrome. Contemp Clin 
Trials 2012; 33: 470–481
Mansson, M., Norstrom, K., Holte, J., Landin-
Wilhelmsen, K., Dahlgren, E., Landen, M. 
Sexuality and psychological wellbeing in 
women with polycystic ovary syndrome 
compared with healthy controls. Eur J Obstet 
Gynecol Reprod Biol 2011; 155: 161–165
McCoy, N.L. The McCoy Female Sexuality 
Questionnaire. Quality of Life Research 2000; 
9: 739–745
Meyer-Bahlburg, H.F., Dolezal, C., Baker, S.W., New, 
M.I. Sexual orientation in women with classical 
or non-classical congenital adrenal hyperplasia 
as a function of degree of prenatal androgen 
excess. Arch Sex Behav 2008; 37: 85–99
Middleton, L.S., Kuffel, S.W., Heiman, J.R. Effects 
of experimentally adopted sexual schemas 
on vaginal response and subjective sexual 
arousal: a comparison between women with 
sexual arousal disorder and sexually healthy 
women. Arch Sex Behav 2008; 37: 950–961
Miner, M., Esposito, K., Guay, A., Montorsi, P., 
Goldstein, I. Cardiometabolic risk and female 
sexual health: the Princeton III summary. J Sex 
Med 2012; 9: 641–651
Mitchell, K.R., Geary, R., Graham, C.A., Datta, J., 
Wellings, K., Sonnenberg, P., Field, N., Nunns, 
D., Bancroft, J., Jones, K.G., Johnson, A.M., 
Mercer, C.H. Painful sex (dyspareunia) in 
women: prevalence and associated factors in 
a British population probability survey. BJOG 
2017; 124: 1689–1697
Mulders, A.G., Eijkemans, M.J., Imani, B., Fauser, 
B.C. Prediction of chances for success or 
complications in gonadotrophin ovulation 
induction in normogonadotrophic anovulatory 
infertility. Reprod Biomed Online 2003; 7: 170–178
Noroozzadeh, M., Tehrani, F.R., Mobarakabadi, S.S., 
Farahmand, M., Dovom, M.R. Sexual function and 
hormonal profiles in women with and without 
polycystic ovary syndrome: a population-based 
study. Int J Impotence Res. 2016
Panidis, D., Tziomalos, K., Papadakis, E., Vosnakis, 
C., Chatzis, P., Katsikis, I. Lifestyle intervention 
and anti-obesity therapies in the polycystic 
ovary syndrome: impact on metabolism and 
fertility. Endocrine 2013; 44: 583–590
Piva, I., Lo Monte, G., Graziano, A., Marci, R. A 
literature review on the relationship between 
infertility and sexual dysfunction: does fun 
end with baby making?. Eur J Contracept 
Reprod Health Care 2014; 19: 231–237
Rosen, R., Brown, C., Heiman, J., Leiblum, 
S., Meston, C., Shabsigh, R., Ferguson, D., 
D’Agostino, R.Jr. The Female Sexual Function 
Index (FSFI): a multidimensional self-report 
instrument for the assessment of female 
sexual function. J Sex Marital Ther 2000; 26: 
191–208
Rotterdam, E.A.-S.P.c.w.g. Revised 2003 
consensus on diagnostic criteria and long-
term health risks related to polycystic ovary 
syndrome (PCOS). Hum Reprod 2004; 19: 
41–47
Sanders, S.A., Graham, C.A., Bass, J.L., Bancroft, 
J. A prospective study of the effects of oral 
contraceptives on sexuality and well-being 
and their relationship to discontinuation. 
Contraception 2001; 64: 51–58
Schwarzer, G. Package ‘meta’ - General Package 
for meta-analysis. CRAN. 2015
Shafti, V., Shahbazi, S. Comparing sexual 
function and quality of life in polycystic ovary 
syndrome and healthy women. J Fam Reprod 
Health 2016; 10: 92–98
Shah, M.B. Obesity and sexuality in women. 
Obstet Gynecol Clin North Am 2009; 36: 
347–360
Snell, W.E., Fisher, T.D., Walter, A.S. The 
Multidimensional Sexuality Questionnaire: An 
objective self-report measure of psychological 
tendencies associated with human sexuality. 
Annals of Sex Research 1993: 27–55
Stovall, D.W., Scriver, J.L., Clayton, A.H., Williams, 
C.D., Pastore, L.M. Sexual function in women 
with polycystic ovary syndrome. J Sex Med 
2012; 9: 224–230
Sutton, A.J., A., K., Jones, D.R., Sheldon, T.A., 
Song, F. Methods for Meta-Analysis in 
medical research. 2000John Wiley & Sons, 
LtdChichester
Tan, S., Hahn, S., Benson, S., Janssen, O.E., Dietz, 
T., Kimmig, R., Hesse-Hussain, J., Mann, K., 
Schedlowski, M., Arck, P.C., Elsenbruch, S. 
Psychological implications of infertility in 
women with polycystic ovary syndrome. Hum 
Reprod 2008; 23: 2064–2071
Thessaloniki, E.A.-S.P.C.W.G. Consensus on 
infertility treatment related to polycystic 
ovary syndrome. Hum Reprod 2008; 23: 
462–477
van den Brink, F., Smeets, M.A., Hessen, D.J., 
Talens, J.G., Woertman, L. Body satisfaction 
and sexual health in Dutch female university 
students. J Sex Res 2013; 50: 786–794
van der Zwan, Y.G., Janssen, E.H., Callens, N., 
Wolffenbuttel, K.P., Cohen-Kettenis, P.T., 
van den Berg, M., Drop, S.L., Dessens, A.B., 
Beerendonk, C. Dutch Study Group on, 
D.S.D.. Severity of virilization is associated 
with cosmetic appearance and sexual function 
in women with congenital adrenal hyperplasia: 
a cross-sectional study. J Sex Med 2013; 10: 
866–875
Veltman-Verhulst, S.M., Boivin, J., Eijkemans, 
M.J., Fauser, B.J. Emotional distress is a 
common risk in women with polycystic ovary 
syndrome: a systematic review and meta-
analysis of 28 studies. Hum Reprod Update 
2012; 18: 638–651
Waldinger, M.D. Psychiatric disorders and sexual 
dysfunction. Handb Clin Neurol 2015; 130: 
469–489
Wells, G.A., Shea, B., O’Connel, D., Peterson, J., 
Welch, V., Losos, M. & Tugwell, P., 2010. The 
Newcastle-Ottawa Scale (NOS) for assessing 
the quality of nonrandomised studies in meta-
analyses.
Wiegel, M., Meston, C., Rosen, R. The female 
sexual function index (FSFI): cross-validation 
and development of clinical cutoff scores. J 
Sex Marital Ther 2005; 31: 1–20
Wierman, M.E., Nappi, R.E., Avis, N., Davis, S.R., 
Labrie, F., Rosner, W., Shifren, J.L. Endocrine 
aspects of women’s sexual function. J Sex Med 
2010; 7: 561–585
Wischmann, T. Sexual disorders in infertile 
couples: an update. Curr Opin Obstet 
Gynecol 2013; 25: 220–222
Wischmann, T.H. Sexual disorders in infertile 
couples. J Sex Med 2010; 7: 1868–1876
Wisniewski, A.B., Migeon, C.J., Malouf, M.A., 
Gearhart, J.P. Psychosexual outcome in 
women affected by congenital adrenal 
hyperplasia due to 21-hydroxylase deficiency. 
J Urol 2004; 171: 2497–2501
Woertman, L., van den Brink, F. Body image and 
female sexual functioning and behavior: a 
review. J Sex Res 2012; 49: 184–211
Zawadzki, J.K., Dunaif, A. Diagnostic criteria for 
polycystic overy syndrome: towards a rational 
approach. 1990National Institute of Child 
Health and Human Development. Blackwell 
Scientific Publications
Zimmerman, Y., Eijkemans, M.J., Coelingh 
Bennink, H.J., Blankenstein, M.A., 
Fauser, B.C. The effect of combined oral 
contraception on testosterone levels in 
healthy women: a systematic review and 
meta-analysis. Hum Reprod Update 2014; 20: 
76–105
Zucker, K.J., Bradley, S.J., Oliver, G., Blake, 
J., Fleming, S., Hood, J. Psychosexual 
development of women with congenital 
adrenal hyperplasia. Horm Behav 1996; 30: 
300–318
Zucker, K.J., Bradley, S.J., Oliver, G., Blake, J., 
Fleming, S., Hood, J. Self-reported sexual 
arousability in women with congenital adrenal 
hyperplasia. J Sex Marital Ther 2004; 30: 
343–355
Zueff, L.N., Lara, L.A., Vieira, C.S., Martins 
Wde, P., Ferriani, R.A. Body composition 
characteristics predict sexual functioning in 
obese women with or without PCOS. J Sex 
Marital Ther 2015; 41: 227–237
Received 16 February 2018; refereed 10 
September 2018; accepted 13 September 2018.
